Skip to main content
. Author manuscript; available in PMC: 2012 Feb 6.
Published in final edited form as: Cancer Chemother Pharmacol. 2010 Jul 2;67(4):919–926. doi: 10.1007/s00280-010-1394-x

Figure 3. Imatinib enhances promoter activation driven by Wnt and MAPK proteins.

Figure 3

MA-11 cells were transduced with ten different lentiviral reporters (Cignal Finder Lenti Cancer 10-Pathway Reporter Array kit, from SABiosciences). After puromycin selection, each reporter cell line was exposed to 25 μM Imatinib for 9 days, followed by a 4-day recovery period (A) or for 24 h (B). The activity of the different pathways was analyzed by a luciferase assay, and expressed as the ratio between the luciferase activity of Imatinib-treated and mock-treated MA-11 cells. Data points are the mean of three separate experiments; bars, SD; *, P<0.05 (ANOVA test).